Non-Small Cell Lung Cancer: Analysis of Late-Stage Pipeline Candidates.
By Hardik Patel, Lead Analyst
26 June 2014
I am Lead Analyst for oncology at Datamonitor Healthcare, based in the New York office. I have a Bachelor of Science deg...
Read full bio
The non-small cell lung cancer (NSCLC) pipeline consists of a variety of different treatment approaches, such as platinum-based chemotherapies, mitotic inhibitors and antimetabolites. However, the movement towards more personalised treatments has become apparent, with targeted treatments dominating the late-stage pipeline.
We have reviewed products in development for non-small cell lung cancer across the US, Japan and five major EU markets providing you with detailed analyses of the leading pipeline candidates, clinical trial design, and future treatment approaches.
How will our non-small cell lung cancer pipeline report help you?
- Optimise your drug strategy
Analysis of the clinical and commercial attributes of key pipeline therapies and comparisons to currently marketed therapies, enabling you to learn what it takes to be successful in the market and capitalize on your opportunities.
- Identify investment opportunities
A detailed look into the unmet needs of patient subgroups outlined by stage, histology, and mutation, helping you target future growth areas within the disease.
- Gain competitive insight
Analysis of the late-stage pipeline including a comparison of the four main pipeline immunotherapies, MEDI-4736, MPDL3280A, nivolumab and pembrolizumab, allowing you to benchmark your drug against the candidates with the most commercial potential.
- Reduce the risk of failure
Understand important clinical trial parameters in non-small cell lung cancer such as patient selection, patient stratification and choice of comparator to increase your drugs likelihood of approval.
Key questions answered
- How do the leading immunotherapies in development for NSCLC compare in terms of both clinical performance and commercial potential?
- Where will novel targeted therapies fit into the market and how will second- generation targeted therapies compare to their predecessors?
- What opportunities remain for drug developers to target niche populations with particular genetic subtypes?
- What type of resistance will target therapies, and other pipeline treatments, face within the market?
- Which candidates within late-stage development are likely to become the first treatments proven to be both safe and effective enough for use in NSCLC?
|Drug List:||Companies Mentioned:|
Posted in Oncology.